Shopping Cart
- Remove All
- Your shopping cart is currently empty
BRCA1-IN-1 is a novel small-molecule-like inhibitor of BRCA1 with an IC50 of 0.53 μM and a Ki of 0.71 μM.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $2,420 | 10-14 weeks | |
50 mg | $3,180 | 10-14 weeks | |
100 mg | $4,300 | 10-14 weeks |
Description | BRCA1-IN-1 is a novel small-molecule-like inhibitor of BRCA1 with an IC50 of 0.53 μM and a Ki of 0.71 μM. |
Targets&IC50 | BRCA1:(ki)0.71 μM , BRCA1:0.53 μM |
In vitro | BRCA1 is a BRCT domain-containing, a tumor-suppressing protein expressed in the cells of breast and other tissues. By targeting the (BRCT)2 domain, BRCA1-IN-1 (Compound 15a) inhibits BRCA1 activities in tumor cells, sensitizes these cells to ionizing radiation-induced apoptosis, and shows the synergistic inhibitory effect when used in combination with Olapari and Etoposide. BRCA1-IN-1 can effectively inhibit HR activity by binding to BRCA1(BRCT)2, and functionally mimic the genetic knockdown of BRCA1. BRCA1-IN-1 is useful in targeting BRCA1/PARP-related pathways involved in DNA damage and repair response, for cancer therapy. |
Molecular Weight | 578.54 |
Formula | C27H33F2N4O6P |
Cas No. | 1622262-74-1 |
Relative Density. | 1.360 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.